EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische Studie

Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study

Thomas Dörner iD, Simon J Bowman, Robert Fox, Xavier Mariette, Athena Papas, Thomas Grader-Beck, Benjamin A Fisher, Filipe Barcelos, Salvatore De Vita, Hendrik Schulze-Koops iD, Robert J Moots, Guido Junge und 5 weitere

Arthritis & Rheumatology · 2025-05 · 77 (5) · 560-570

DOI: 10.1002/art.43059 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Arthritis & Rheumatology, online erschienen am 05.01.2025. Verfasst von Thomas Dörner und 16 weiteren Autor:innen. Beteiligte Einrichtung: Charite Universitätsmedizin, Berlin, Germany. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Antibodies, Monoclonal. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: The study was funded by Novartis Pharma AG, Basel, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study was to report 52‐week safety and efficacy of ianalumab from phase 2b dose‐finding study in patients with Sjögren's disease (SjD).

Methods

Patients randomly received (1:1:1:1) ianalumab (5, 50, or 300 mg) or placebo subcutaneously every 4 weeks until week 24 (treatment period [TP]1). At week 24, patients on 300 mg were rerandomized to continue 300 mg or receive placebo until week 52 (TP2), patients on placebo were switched to ianalumab 150 mg, and patients on 5 and 50 mg directly entered posttreatment safety follow‐up. Patients who discontinued treatment early or completed treatment entered safety follow‐up (≥20 weeks).

Results

During TP1, 190 patients were randomized (placebo = 49, 5 mg = 47, 50 mg = 47, 300 mg = 47). Of these 190 patients, 90 (47.4 %; 43 continued 300 mg and 47 received placebo) entered TP2, and 81 of 90 (90.0%) completed the study treatment. By week 52, efficacy was sustained in patients who continued 300 mg in TP2 (EULAR Sjögren's Syndrome Disease Activity Index, EULAR Sjögren's Syndrome Patient Reported Index, patient global assessment, and physician global assessment change from week 24: −1.45, −0.46, −4.69, and −6.86, respectively). Stimulated salivary flow rates and autoantibody levels numerically improved in the 300 mg group. Treatment‐emergent adverse events were not dose‐dependent, except for injection‐site reactions. Cases of decreased neutrophil counts (Common Terminology Criteria for Adverse Events v4.03 grade 3 according to laboratory listings) were observed in three patients during the posttreatment follow‐up, occurring at 3.5, 5.5, and 3 months, after the last ianalumab administration. None were associated with infection except one incidental finding of asymptomatic cytomegalovirus infection (IgM‐positive).

Conclusion

In patients with SjD, ianalumab 300 mg demonstrated sustained efficacy through week 52 and a favorable safety profile up to two years of follow‐up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sjogren's SyndromeAntibodies, MonoclonalHumansFemaleMiddle AgedMaleDose-Response Relationship, DrugAdultTreatment OutcomeAgedDouble-Blind MethodAntibodies, Monoclonal, HumanizedInjections, Subcutaneous

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Charite Universitätsmedizin, Berlin, Germany.
  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Scripps Memorial Hospital and Research Institute, La Jolla, California.
  • Université Paris-Saclay, Paris, France, and Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France.
  • Tufts School of Dental Medicine, Boston, Massachusetts.
  • Johns Hopkins School of Medicine, Baltimore, Maryland.

ORCID-Profile: Thomas Dörner, Hendrik Schulze-Koops

Förderung

  • The study was funded by Novartis Pharma AG, Basel, Switzerland

Zitieren

APA

Dörner, T., Bowman, S. J., Fox, R., Mariette, X., Papas, A., Grader-Beck, T., Fisher, B. A., Barcelos, F., De Vita, S., Schulze-Koops, H., Moots, R. J., Junge, G., Woznicki, J., Sopala, M., Avrameas, A., Luo, W. L., & Hueber, W. (2025). Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study. Arthritis & Rheumatology, 77(5), 560-570. https://doi.org/10.1002/art.43059

Vancouver

Dörner T, Bowman SJ, Fox R, Mariette X, Papas A, Grader-Beck T, et al. Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study. Arthritis & Rheumatology. 2025;77(5):560-570. doi:10.1002/art.43059

BibTeX
@article{Drner2025,
  author = {Dörner, Thomas and Bowman, Simon J and Fox, Robert and Mariette, Xavier and Papas, Athena and Grader-Beck, Thomas and Fisher, Benjamin A and Barcelos, Filipe and De Vita, Salvatore and Schulze-Koops, Hendrik and Moots, Robert J and Junge, Guido and Woznicki, Janice and Sopala, Monika and Avrameas, Alexandre and Luo, Wen-Lin and Hueber, Wolfgang},
  title = {Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  volume = {77},
  number = {5},
  pages = {560--570},
  doi = {10.1002/art.43059}
}
Kostenlos starten →